Mangoceuticals, Inc. — Form 8-K Summary
Business Context and Reporting Period
Mangoceuticals, Inc. filed a Form 8-K dated November 3, 2023, reporting a Nasdaq continued-listing deficiency based on stockholders’ equity reported in its Quarterly Report on Form 10-Q for the period ended September 30, 2023.
Key Financial Metrics and Liquidity
- Stockholders’ equity as of September 30, 2023: $1,354,821.
- Nasdaq Capital Market minimum stockholders’ equity requirement: $2,500,000.
- The filing does not provide clear values for revenue, net income, cash flow, margins, debt, cash, or other liquidity metrics.
Material Changes and Listing Status
On November 3, 2023, Nasdaq notified the company that its stockholders’ equity was below the requirement of Nasdaq Listing Rule 5550(b)(1). The company also stated that it did not meet the alternative Nasdaq continued-listing standards.
The notice did not immediately affect the listing or trading of the company’s common stock on Nasdaq. The company’s shares remained listed and traded, subject to compliance with other continued-listing requirements.
Management Commentary, Outlook, and Risks
- The company must submit a plan to regain compliance by December 18, 2023.
- If Nasdaq accepts the plan, it may grant an extension of up to 180 calendar days from the date of its letter to demonstrate compliance.
- Management stated that it is evaluating courses of action, intends to submit a timely compliance plan, and is confident it can regain compliance within the applicable period.
- There is no assurance that Nasdaq will accept the plan or that the company will regain compliance.
- The company also reported that it was not currently in compliance with Nasdaq’s minimum bid-price requirement of $1.00 per share.
- If the plan is rejected, compliance is not achieved within the permitted period, or another listing requirement is not satisfied, Nasdaq could initiate delisting proceedings. The company may appeal an adverse decision to a Nasdaq Hearings Panel.
Important Facts for Investors to Verify
- Whether the company submitted its compliance plan by December 18, 2023.
- Whether Nasdaq accepted the plan and granted an extension.
- Whether the company restored stockholders’ equity to at least $2.5 million.
- Whether the company resolved its minimum bid-price deficiency.
- Any subsequent Nasdaq delisting notice, hearing decision, or change in trading status.